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Introduction
Adverse drug events (ADEs), referring to any undesirable effect of a drug beyond its anticipated therapeutic effects occurring during clinical use 1 , are important public health concerns. Although randomized clinical trials (RCTs) are considered a gold standard in identifying pre-marketing safety issues of drugs, there are some existing limitations, primarily within experiments. These limitations can include insufficient patient number, homogeneous population, short trial period and exclusion of patients with comorbid diseases. Therefore, it is well accepted that pre-marketing RCTs may not detect all types of ADEs related to a particular drug in clinical practice.
In post-marketing surveillance for adverse drug events (ADEs), the FDA's Adverse Event Reporting System (AERS) has become an important resource. However, signals from AERS data may contain false positive results, where an association between the drug and ADE is incorrectly identified, as well as false negative results, where a true association or signal is missed. Other data sources have been studied aiming for ADE detection, such as the secondary use of Electronic Medical Records (EMRs) for further validation or comparison of ADEs, which has been paid much attention. EMRs contain rich information in unstructured clinical notes that cannot be overlooked 2 . Recently, Natural language processing (NLP) has been used to extract drug-ADE pairs for signal detection through χ2 test 3 . The efficacy of mining EMRs for drug-ADE relationship has also been proven 4 . As a demonstration that combining AERS with EHRs can improve the accuracy of ADE signal detection, an approach was proposed to produce a highly selective ranked set of candidate ADEs from both AERS and EMRs based on proportionality analysis 5 . This study could systematically discover ADEs and apply to very general scenarios.
In this study, we proposed a framework where the ADEs associated with interested drugs are discovered from FDA AERS, and then validated through mining unstructured clinical notes where clinical priorities are given in terms of cohort selection and result analysis. To demonstrate the methodology, we investigate potential ADEs associated with drugs (class level) for rheumatoid arthritis (RA) patients.
Background
Rheumatoid arthritis (RA) is the most common type of arthritis in adults in the United States 6 . Conventional diseasemodifying anti-rheumatic drugs (DMARDs), including methotrexate (MTX), sulfasalazine, and leflunomide, have been the cornerstone of the treatment of rheumatoid arthritis (RA). Recently biological agents (biologics), for example etanercept, demonstrated major therapeutic advances in treating RA patients 7 .
In clinical practice, the safety of medications for RA patients is an important issue. Many studies focus on adverse drug events (ADEs) associated with either DMARDs or biologics, or their combination, through randomized controlled trials (RCTs) 8 , clinical trials 9 , systematic reviews 10 , meta-analysis 11 , and chart reviews 12 . Because RCTs or clinical trials are not able to reveal all potential ADEs due to experimental limits, post-marketing surveillance becomes an important means of evaluating drug safety. The FDA Adverse Event Reporting System has been used for the discovery of ADEs associated with biologics for RA, mainly aiming at specific ADEs, i.e., ischaemic colitis 13 ,T-cell non-Hodgkin's lymphomas 13 , neurological events 14 , and pneumocystis 15 . In one study, several data sources were used to compare the magnitude of serious adverse events (SAEs) observed in post-marketing reports of tocilizumab (TCZ), one of the biologics for RA patients 16 . However, ADEs are not systematically discovered. Interested ADEs included only serious hepatic events, gastrointestinal perforation, and cardiovascular events (myocardial infarction and stroke). In this study, we aim to systematically discover ADEs associated with two drug classes (conventional DMARDs and biologics) based on the framework we propose. Figure 1 shows the framework for ADE mining from FDA's AERS and EMRs that includes three steps: preprocessing, signal detection and validation. In preprocessing, NLP was conducted for clinical notes in the EMRs. During the signal detection, interested drugs were first identified from the AERS data mining set (AERS-DM), and then data mining algorithms such as reporting odds ratios (ROR) were conducted to generate potential ADE signals. For the EMRs, interested drugs, the cohort on interested drugs, and outcomes were identified, and then the outcomes before drug use were removed. Lastly, the overlap between ADE signals and outcomes from EMR was further investigated to discover potential ADEs. The details are shown below. 
Materials and Methods

Data Sources
The FDA's AERS is a database supporting the post-marketing safety surveillance for drug and therapeutic biologic products 17 . However, this database contains redundant data where drugs can also be registered by arbitrary names, including trade names, abbreviations, and even typographical errors. In order to make it convenient for complicated downstream analysis, we previously produced a normalized knowledge-enhanced data mining set based on AERS, i.e., AERS-DM 18 . Three steps were conducted: de-duplication, drug normalization, and data aggregation. First, redundant reports were removed as suggested by the FDA. This procedure removed multiple reports of the same event. Second, FAERS drug names, along with administration route and dose information, were normalized using a natural language processing (NLP) tool MedEx 19 to RxNorm, a standardized nomenclature for clinical drugs and drug delivery devices 20 . Meanwhile, adverse event terms were mapped to Medical Dictionary for Regulatory Activities (MedDRA)'s preferred term (PT) code and classified into MedDRA System Organ Class (SOC) 21 . Third, adverse events were aggregated according to MedDRA SOC and PT codes, and drugs were aggregated based on National Drug File-Reference Terminology (NDF-RT) classification information through RxNorm 22 .
We processed FAERS data from 2004 through 2011 into AERS-DM, which contains 37,029,228 ADE records. In total, 74% of FAERS unique drug names were normalized to 14,489 unique RxNorm concepts, of which 10,221 (71%) were classified in NDF-RT. The datasets of AERS-DM can be downloaded from the website http://informatics.mayo.edu/adepedia/index.php/Download.
EMR clinical notes in our study consist of a cohort of Employee and Community Health (ECH) patients receiving their primary care at Mayo Clinic over a period of 15 years (1998-2013) . This cohort include 138,000 patients and covers both inpatient and outpatient settings. Problems (outcomes) in those notes are generally entries which are itemized as either phrases (e.g., Allergic rhinitis/vasomotor rhinitis) or short sentences (e.g, Her asthma appeared to be very mild). In this study, we chose sections related to diagnosis and lab tests for ADE detection.
Preprocessing
To align with the meaningful use requirement, the CORE Problem List Subset was created to better implement Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) in EMRs
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. The CORE Problem List Subset offers a good coverage of frequently used terms in problem lists 23 . In a previous study 24 , we assessed the coverage of SNOMED CT for codifying problem lists in narrative format by extracting itemized entries from clinical notes 25 . In this study, we normalized them to the Unified Medical Language System (UMLS) concepts. We applied the same methodology but kept UMLS concepts that can be mapped to the CORE Problem List Subset codes (the August 2015 version of The CORE Problem List Subset of SNOMED CT was used). Then MedXN was used for the normalization of medications in this cohort to RxNorm codes 26 .
Signal detection
DMARDs and biologics are two drug classes for the treatment of RA. DMARDs include methotrexate, leflunomide, hydroxychloroquine and sulfasalazine. Biologics include abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab and tofacitinib.
From AERS-DM, RxNorm codes of these generic ingredients were used to extract records. Drug indications were limited for RA patients. The data mining method reporting odds ratio (ROR) was used to detect associations between drug class DMARDs, biologic use, and ADEs. The calculation of ROR is based on a 2×2 contingency table 27, 28 . The number of reports with drug class and ADE is defined as a. The number of reports with drug class and without ADE is defined as b. The number of reports with drugs other than this drug class and with ADE is defined as c. The number of reports with drugs other drug class and without ADE is defined as d. In this analysis, the lower bound of the 95% confidence interval of the ROR was used 29 . R package PhViD 1.0.6 was used for signal detection 30 .
From the normalized data of clinical notes in EMRs, first, synonyms of RA from UMLS were used to identify RA patients, i.e., rheumatoid arthritis or polyarthritis rheumatic. Associated medications, prescription date, and diagnosis date were also extracted. Second, patient cohorts were identified in consideration of clinical priorities based on interested drugs and indications. To study the drug class DMARDs, we identified the cohort of RA patients as those who took any drug in the DMARDs class without drugs of biologics. According to the 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, conventional DMARDs are usually used for early RA patients, while biologics are often used for moderate or high disease activity, combining with or without DMARDs 31 . To study the drug class biologics, we identified another cohort of RA patients as those who took any drugs within the biologics class, no matter if a drug in the DMARDs class was used in combination. This is also simulating the condition from AERS-DM where data mining of biologics for RA did not consider if DMARSs were used in combination. Therefore, two different cohorts were used for two drug classes. Third, the outcomes of patients from the two cohorts were identified respectively. Forth, outcomes before the administration of interested drugs were removed to obtain possible ADE signals, i.e., possible consequences of interested drugs.
Validation
After obtaining signals associated with DMARDs and biologics from AERS-DM, MedDRA PT codes were mapped to 2012AB UMLS concepts. The overlapping signals for the two drug classes were further analyzed through mapping PT terms to System Organ Class (SOC) terms. For each drug class, we manually compared the overlapping signals to filter confirmed ADEs from package inserts, and then complications and other confounding factors were filtered to reveal potential ADEs. Some examples were shown using top overlaps of outcomes associated with biologics and DMARDs chosen according to the criteria of ROR more than 2, reporting number in AERS-DM more than 5, and incidence from EMR more than 5%.
Results
In total, there were 497 unique patients with an RA (or synonyms) diagnosis who took only DMARDs, and 365 unique patients with an RA (or synonyms) diagnosis who took biologics no matter if DMARDs were coadministered. Table 1 shows signals from AERS-DM and outcomes from clinical notes. More signals were detected for biologics (152) from both AERS-DM and clinical notes than DMARDs (147). The overlapping signals for the two drug classes were further analyzed through mapping PT terms to System Organ Class (SOC) terms. Table 2 shows the number of PT terms (signals) for DMARDs and biologics mapping to SOC. Potential ADEs associated with biologics were involved in more SOCs than those with DMARDs, and the top 6 SOCs were in the same order for potential ADEs associated with both drug classes. For each drug class, we manually compared the overlapping signals with confirmed ADEs from package inserts. Table 3 shows the analysis results. Signals were divided into four categories, the first is confirmed ADEs or signs of ADEs in package inserts such as "vasculitis" for biologics, the second is complications of RA such as "osteoporosis", the third is treatments such as "appendectomy", and the forth is potential ADEs such as "hyperkeratosis" for biologics. The top potential ADEs associated with biologics and DMARDs were chosen according to the criteria of ROR more than 2, reporting number in AERS-DM more than 5, and incidence from EMR more than 5%. Table 3 and Table 4 show the top potential ADEs for DMARDs and biologics, case number from clinical notes and percentage, report number from AERS-DM, and ROR.
In Table 4 , there are 15 signals above the thresholds for DMARDs. There are 7 signals (46%) confirmed as ADEs or signs of ADEs in package inserts, shown in bold and italic. There are 4 signals (27%) identified as complications of RA, shown in italic. Four signals (27%) "Endometrial cancer", "bladder neoplasm", "Sjogren's syndrome", and "Amyotrophic lateral sclerosis" could be possible ADEs following DMARDs that can't be found in package inserts. 
Discussion
In this study, we demonstrated the framework by exploring potential ADEs associated with drugs for RA patients. ADEs associated with drug class DMARDs and biologics for RA patients were first systematically mined from AERS-DM. Corpuses of RA patients on each drug class were then carefully selected according to the clinical guidelines. Following that, outcomes following drug uses were revealed from unstructured EMRs, and the overlaps between the signals and the outcomes of RA patients on these drugs were further analyzed to identify potential ADEs. RA is a systemic autoimmune disease with the characteristics of chronic inflammation that results in a destructive polyarthritis. Many complications may occur after RA. Therefore, we fully considered the features of RA to exclude possible complications from overlaps between signals from AERS-DM and outcomes from EMRs.
In view of various regimens used among different institutions, some drugs used in one institution may not be used in another. EMR data from only a single institution, i.e., Mayo Clinic, was used in this study. To avoid omitting information on drugs and indications, our method doesn't aim for screening whole databases as done in the previous study 5 . Instead, demonstrated as a framework interfacing informatics domain and medical domain, it employed more refined strategies based on interested drugs and indications. In the future, we will develop more general methodology once EMR data from multiple institutions, such as Optum lab, can be obtained.
Some adverse events occur after a short time following drug use, from several minutes to several hours. Others occur only after several days, weeks, months or even years of exposure 4 . Therefore, when extracting outcomes, we have not limited the time of outcome occurrence after drug use. This allows detection of late-onset events. However, it may be interesting to observe the difference of time of outcome occurrences in the future.
During the result analysis, we found that potential ADEs such as "Endometrial cancer" and "bladder neoplasm" for conventional DMARDs could also be the natural consequences of RA. Because the disease is a systemic autoimmune disease, patients with RA are at an increased risk for cancer 32 . In the future, we will integrate casecontrol study design into the framework based on EMR data to further discriminate such potential ADEs from comorbidities with indications of interested drugs.
Conclusions
We proposed a framework for discovering potential ADEs associated with drugs combining both FDA AERS and EMRs. This framework has two features. First, more priority was given to clinical practice. Second, the normalization by NLP facilitated the interoperation between AERS-DM and EMRs. The results demonstrated the feasibility and sufficient accuracy of the framework. The framework can serve as the interface between the informatics domain and the medical domain to facilitate ADE discovery.
